Close

Pfizer (PFE), Medivation (MDVN) Report Dimebon Does Not Report Statistically Significant Results in Phase 3 HORIZON

April 11, 2011 7:33 AM EDT
Pfizer Inc (NYSE: PFE) and Medivation, Inc. (Nasdaq: MDVN) report the following results from the Phase 3 HORIZON trial of the investigational drug dimebon (latrepirdine*) in patients with Huntington disease.

Dimebon did not achieve statistical significance for either of the co-primary endpoints, the Mini-Mental State Examination (MMSE), which measures cognition (p=0.39), or the Clinician's Interview-Based Impression of Change, plus caregiver input (CIBIC-plus), which measures global function (p=0.84).


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA, Hot FDA News, Trading Halts